Tesamorelin reduces visceral fat while leaving subcutaneous fat largely untouched. That selectivity comes from the growth hormone axis, the same GHRH receptor that compounded sermorelin acts on.
Tesamorelin targets visceral fat specifically, the metabolically active fat packed around the abdominal organs, not the subcutaneous fat directly under the skin. In trials it reduced visceral adipose tissue by 15 to 17% while leaving subcutaneous fat largely unchanged [1][2]. That selectivity is the point of the drug, and it comes from the growth hormone axis.
- Tesamorelin reduces visceral fat, the fat around the organs, not subcutaneous belly fat [4]
- Visceral fat fell 15.2% over 26 weeks in the largest trial, versus a 5.0% rise on placebo [1]
- The effect works through GH-stimulated lipolysis in the visceral compartment [4]
- It is FDA-approved only for HIV-associated lipodystrophy [5]
- Compounded sermorelin acts on the same GHRH receptor and is the prescribable GH-axis option for age-related decline
Visceral Fat Is Not the Same as Belly Fat
The distinction matters clinically. Subcutaneous fat sits under the skin and is what you can pinch. Visceral fat sits deeper, wrapped around the liver, intestines, and other organs, and it is the metabolically active compartment tied to insulin resistance and cardiovascular risk. Tesamorelin acts on the visceral compartment, which is why its results show up on a CT scan more than in the mirror.
- Subcutaneous fat: under the skin, pinchable, lower metabolic risk
- Visceral fat: around the organs, measured by CT, tied to metabolic and cardiovascular risk
- Tesamorelin selectively reduces the visceral compartment [4]
- Total body weight and subcutaneous fat change little on tesamorelin [1]
How the GH Axis Reduces Visceral Fat
Growth hormone drives lipolysis, the breakdown of stored fat, and visceral fat is particularly responsive to it. By raising GH and IGF-1, tesamorelin increases fat mobilization from the visceral depot [4]. The mechanism is indirect: the drug stimulates the pituitary, GH rises in pulses, and the metabolic effect follows. This is the same GH-axis pathway that links declining GH output to increased abdominal fat with age.
Age-related decline in GH output is associated with a shift toward visceral fat accumulation. Restoring GH pulsatility through a GHRH analog targets that specific mechanism, which is different from how GLP-1 drugs or calorie restriction reduce fat.
The Evidence for Visceral Fat Reduction
The visceral fat effect is one of the better-documented outcomes in GHRH pharmacology. In the 412-patient registration trial, visceral adipose tissue fell 15.2% over 26 weeks against a 5.0% increase on placebo [1]. A pooled analysis of 806 patients found a 15.4% effect at 26 weeks and 17.5% at 52 weeks [2], and a 404-patient trial reported 10.9% at 6 months [3]. A review of GHRH effects on visceral fat across human studies confirms the pattern is consistent [4].
Visceral fat reaccumulated after tesamorelin was stopped [3]. The drug manages the depot rather than permanently clearing it, so the effect depends on continued use.
Who This Applies To
Tesamorelin is approved only for excess abdominal fat in HIV-infected adults with lipodystrophy [5]. That is a specific medical population with a specific pattern of visceral accumulation. Using it for ordinary age-related belly fat is off-label, and its specialty pricing makes it an impractical choice for that goal.
- Approved population: adults with HIV-associated lipodystrophy and excess visceral fat [5]
- Off-label for general abdominal fat, and priced as a specialty drug
- Not a treatment for subcutaneous fat or overall weight
- Not FDA-approved for anti-aging or cosmetic goals
The Sermorelin and GH-Axis Alternative
For someone without HIV-lipodystrophy who wants the GH-axis lever on visceral fat, the prescribable option is compounded sermorelin. It acts on the same GHRH receptor and raises IGF-1 through the same pathway, though its adult evidence is thinner and it is not FDA-approved. A controlled trial of a close GHRH(1-29) analog found IGF-1 elevation within 2 weeks and increased lean mass in men, but no significant fat mass change over 16 weeks [6], which sets a realistic expectation: visceral fat change through the GH axis is gradual and needs roughly 6 months to assess.
Sermorelin is not a weight-loss drug, and it will not match a GLP-1 medication for scale weight. What it offers is a GH-axis approach to body composition, prescribed by a physician against a baseline IGF-1. The honest framing is a modest, mechanism-specific tool, not a shortcut.
A GHRH protocol targets visceral fat through the GH axis over months, confirmed by IGF-1 testing. It is not a substitute for GLP-1 therapy, resistance training, or a calorie deficit when the goal is overall weight loss.
Tesamorelin is limited to HIV-associated lipodystrophy. Compounded sermorelin works through the same GHRH receptor and is what physicians prescribe for age-related GH decline. SystemLabs includes a baseline IGF-1 before prescribing, so any visceral fat goal is tracked against a real lab starting point.
The Bottom Line
Tesamorelin genuinely reduces visceral fat, but only within its approved HIV-lipodystrophy indication, and the effect reverses when the drug stops [1][3]. For age-related abdominal fat, the GH axis is a modest lever best accessed through compounded sermorelin under physician supervision, with a baseline IGF-1 and a 90-day retest. Anyone promising rapid belly-fat loss from a GHRH peptide is overselling what the evidence supports.
Frequently Asked Questions
Does tesamorelin reduce belly fat?
It reduces visceral fat, the deep fat around the abdominal organs, rather than the subcutaneous fat you can pinch. In the largest trial, visceral adipose tissue fell 15.2% over 26 weeks versus a 5.0% rise on placebo [1]. Subcutaneous fat and total body weight changed little, so the change is more internal than visible [4].
How does tesamorelin target visceral fat specifically?
It works through the growth hormone axis. By stimulating the pituitary to release GH, tesamorelin increases lipolysis in the visceral fat compartment, which is particularly responsive to GH [4]. The effect is indirect and gradual, developing over months rather than weeks.
Is tesamorelin good for age-related belly fat?
It is not approved or practical for that. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy [5], and it is priced as a specialty injectable. For age-related abdominal fat linked to declining GH output, the prescribable GH-axis option is compounded sermorelin, which acts on the same receptor.
Will visceral fat come back after stopping tesamorelin?
Yes. Visceral fat reaccumulated after the drug was discontinued in the trials [3]. Tesamorelin manages the visceral depot rather than permanently clearing it, so the result depends on continued use. Expect gradual reversal after a fixed-length course.
Is tesamorelin or sermorelin better for losing belly fat?
Neither is a general weight-loss drug, and both work through the same GHRH receptor. Tesamorelin has stronger visceral fat evidence but is limited to HIV-lipodystrophy and priced as a specialty product [5]. Sermorelin has thinner adult data [6] but is the compounded option physicians actually prescribe for age-related decline. For overall weight loss, a GLP-1 medication has stronger direct evidence than either.
References
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes, 2010. PMID: 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2010. Initial U.S. Approval: 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
